Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreichs Ataxia on Monday, May 18, 2026
May 17, 2026 16:00 ET | Source: Design Therapeutics, Inc. CARLSBAD, Calif.,…
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto in metastatic hormone-sensitive prostate cancer
More durable, deeper PSA response in patients treated with Pluvicto plus standard…
Huawei and Partners Receive GSMA Global Mobile LATAM Award for Tech4Nature Mexico Project to Protect Jaguars
MEXICO CITY, May 14, 2026 /PRNewswire/ -- Huawei received the Global Mobile…
Blockchain.com Unveils Highly Anticipated Crypto-Backed Loans, Bringing Borrowing To Crypto Holders Worldwide
The company launches in-house lending for global users starting at 1.9%, delivering…
Artmarket.com: The Artprice Manifesto: 22 Rules for a Regulated and Transparent Art Market in the Age of AI
Artificial intelligence is redistributing the value of information at an unprecedented pacePARIS,…
Crypto News: AlphaPepe Presale Records Surge in Whale Accumulation As Bitcoin Price Prediction Eyes $180,000
MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward…
Crypto Market News: AlphaPepe Finalizes Tier-1 Exchange Shortlist as XRP Price Prediction Targets $5.00
MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning…
Qoder Version 1.0 Released: Full Automation of Code Generation, Verification & Delivery
SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0,…
Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction
Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to…
ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026
– Complete response (CR) observed in 70% (50/72) of evaluable patients with…
